Generic Medicine Info
Indications and Dosage
Brucellosis, Cholera, Cat scratch disease, Typhus, Murine typhus, Mediterranean spotted fever, Rocky Mountain spotted fever, Q fever, Mycoplasma infections, Ornithosis, Psittacosis, Borreliosis, Chlamydial infections, Gonorrhoea
Adult: 600 mg daily in 2 divided doses.
Renal Impairment
Dose reduction may be required.
Hypersensitivity. Pregnancy and lactation. Children ≤12 yr.
Special Precautions
Avoid direct sunlight. Renal and hepatic impairment.
Adverse Reactions
Hypersensitivity reactions, urticaria, photosensitivity, fever, epigastric pain, anorexia, nausea, vomiting, diarrhoea, oral candidiasis, vulvovaginitis, glossitis, pruritus ani, increased intracranial pressure, teeth and nail discolouration, renal dysfunction, hepatomegaly, enamel hypoplasia, neuromuscular blockade.
Potentially Fatal: Anaphylaxis. Severe renal impairment, fatty liver.
Drug Interactions
Absorption reduced by divalent and trivalent cations (e.g. aluminium, bismuth, calcium, iron, magnesium, zinc), sodium bicarbonate, colestipol, colestyramine, kaolin-pectin. May form complex with strontium ranelate. Increased nephrotoxic effects with diuretics, methoxyflurane, other nephrotoxic drugs. Additive hepatotoxicity with potentially hepatotoxic drugs. May increase incidence of benign intracranial hypertension with retinoids. May increase concentrations of lithium, digoxin, halofantrine, theophylline. May increase effects of oral anticoagulants, ergot alkaloids and methotrexate. May reduce plasma levels of atovaquone. May decrease the effectiveness of oral contraceptives. Possible antagonism with penicillins.
Food Interaction
Avoid dairy and milk products.
Lab Interference
May interfere with determination of urinary catecholamines or glucose.
Mechanism of Action: Metacycline prevents the binding of aminoacyl transfer RNA in the ribosome 30S subunit. This inhibits protein synthesis and hence cell growth. It is bacteriostatic and has a broad spectrum of antibacterial activity.
Absorption: Incomplete absorption (58%) from the GI tract (oral).
Distribution: Protein-binding: 75%. Crosses the placenta and distributes in breast milk. Widely distributed in tissues, bones, teeth.
Excretion: Via urine, faeces and saliva. Not dialysable. Elimination half-life: Approx 14 hr.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Metacycline from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in